Hamburg FDA May Look Favorably On Anti-infectives For Serious Conditions
Executive Summary
Anti-infective drug developers may see new opportunities for a favorable regulatory review climate for products for a few serious conditions, based on FDA's public health-oriented top management team under new Commissioner Margaret Hamburg and Deputy Commissioner Joshua Sharfstein